# Altimmune, Inc. (ALT) Stock Analysis: Exploring a 445% Potential Upside with Strong Buy Ratings - Link: https://www.directorstalkinterviews.com/altimmune-inc-alt-stock-analysis-exploring-a-445-potential-upside-with-strong-buy-ratings/4121245637 - Published: 2026-03-20T11:35:03+00:00 - Author: Madison Wilson Altimmune, Inc. (NASDAQ: ALT), a promising player in the biotechnology sector, is capturing the attention of investors with its significant potential upside and compelling analyst ratings. The company, headquartered in Gaithersburg, Maryland, specializes in developing innovative therapies for serious liver diseases, and its lead product candidate, pemvidutide, is currently in Phase 3 clinical trials. **Market Position and Price Dynamics** With a market capitalization of $428.29 million, Altimmune is positioned as a mid- sized entity within the highly competitive healthcare industry. The company’s stock is currently priced at $3.42, showing no percentage change from its previous close. Over the past 52 weeks, the stock has fluctuated between $3.38 and $7.71, reflecting its volatility and the dynamic nature of biotech investments. **Valuation and Financial Health** Altimmune’s valuation metrics reveal a complex picture. The company does not have a trailing P/E ratio, and its forward P/E stands at -2.51, highlighting challenges in achieving profitability in the near term. This negative P/E is common in the biotechnology sector, where companies may not generate positive earnings until their products receive regulatory approval and achieve market penetration. Despite this, the company’s impressive revenue growth of 420% signals robust business development and successful advancement in its clinical trials. However, the financial performance metrics indicate some concerns. The net income is not available, and the company reported an EPS of -1.00. Its return on equity is notably negative at -50.57%, and free cash flow stands at -$38.72 million, suggesting that Altimmune is investing heavily in its R&D pipeline, which is typical for companies at this stage of clinical development. **Analyst Ratings and Investor Outlook** Altimmune is predominantly viewed favorably by analysts, with eight buy ratings, one hold, and one sell rating. The consensus average target price of $18.67 presents a staggering potential upside of 445.81% from the current price, indicating strong confidence in Altimmune’s future prospects and the potential success of its therapeutic candidates. The target price range is notably wide, from $1.00 to $28.00, underscoring the inherent risks and rewards associated with investing in biopharmaceutical companies. This variability suggests that while there is significant potential for high returns, investors must also be prepared for the volatility that can accompany clinical trial outcomes and regulatory decisions. **Technical Indicators and Market Sentiment** From a technical analysis standpoint, Altimmune’s stock is currently trading below both its 50-day and 200-day moving averages of $4.44 and $4.38, respectively. This positioning suggests a bearish trend in the short-term. The RSI (Relative Strength Index) of 26.37 indicates that the stock is in oversold territory, which might present a buying opportunity for contrarian investors seeking to capitalize on potential price rebounds. The MACD (Moving Average Convergence Divergence) of -0.30, with a signal line at- 0.27, further corroborates the bearish sentiment. These indicators suggest that while the stock has faced recent selling pressure, there could be room for recovery if positive catalysts emerge, such as favorable trial results or strategic partnerships. **Final Thoughts** Altimmune, Inc. presents a high-risk, high-reward opportunity typical of the biotechnology sector. Its focus on addressing critical liver diseases with its lead candidate, pemvidutide, positions it as a company with significant potential if clinical trials succeed. Investors with a tolerance for volatility and a long-term perspective may find Altimmune an intriguing addition to their portfolios, given the strong buy ratings and potential upside. However, it remains crucial to monitor clinical developments and market conditions closely. Share on: